Summarized by Masters of Longevity from Nature Aging.
A year-long randomized trial found no clinical benefit from NAD+ precursor.
Key Takeaways
- A year-long trial was negative for nicotinamide riboside benefit.
- Self-reported motor and nonmotor symptoms were not improved versus placebo.
- Imaging and NAD+ analyses were not supportive of disease modification.